Download PDF
Exp Clin Endocrinol Diabetes 2017; 125(02): 116-121
DOI: 10.1055/s-0042-118961
Article
© Georg Thieme Verlag KG Stuttgart · New York

EndoBarrier Gastrointestinal Liner in Type 2 Diabetic Patients Improves Liver Fibrosis as Assessed by Liver Elastography

K. S. C. Gollisch
,
A. Lindhorst
,
D. Raddatz
Further Information

Publication History

received 12 July 2016
revised 26 September 2016

accepted 12 October 2016

Publication Date:
22 December 2016 (online)

Also available at
    Permissions and Reprints

Abstract

Many obese people with type 2 diabetes develop non-alcoholic fatty liver disease, which may progress to liver fibrosis. EndoBarrier gastrointestinal liner is an innovative interventional treatment option for type 2 diabetic patients, which could affect diabetes associated liver disease. The aim of this retrospective study was to analyze the effect of 1-year EndoBarrier therapy on liver fibrosis and steatosis. As an indicator of fibrosis, liver stiffness was assessed by liver elastography at baseline, 2 weeks after EndoBarrier implantation and then every 3 months until explantation. 13/19 patients had elevated liver stiffness at baseline, corresponding to liver fibrosis grade 2 to 4. In these patients, liver stiffness reduced significantly during EndoBarrier therapy from 10.4 kPa (IQR 6.0–14.3) at baseline to 5.3 kPa (IQR 4.3–7.7, p<0.01) by the time of EndoBarrier explantation, corresponding to a normalization of the initially pathologic findings in most patients. Liver steatosis was also assessed by elastographic measurements in terms of the controlled attenuation parameter. In all patients, baseline measurements showed high grade steatosis. Improvements were seen from initially 343 dB/m (IQR 326–384) to 317 dB/m (IQR 269–375, p<0.05) by the time of explantation. However, most patients were still classified high grade steatosis after completion of EndoBarrier treatment. In this observational study, we show that liver fibrosis is a common condition in obese patients suffering from type 2 diabetes, and that EndoBarrier gastrointestinal liner substantially improves liver fibrosis in these patients.

Key words

NAFLD - steatosis - Obesity - fibroscan - liver stiffness
 

  • References

  • 1 Younossi ZM, Koenig AB, Abdelatif D et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84
    CrossrefPubMedGoogle Scholar
  • 2 Leite NC, Salles GF, Araujo AL et al. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009; 29: 113-119
    CrossrefPubMedGoogle Scholar
  • 3 Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013; 10: 330-344
    CrossrefPubMedGoogle Scholar
  • 4 de Moura EG, Martins BC, Lopes GS et al. Metabolic improvements in obese type 2 diabetes subjects implanted for 1 year with an endoscopically deployed duodenal-jejunal bypass liner. Diabetes Technol Ther 2012; 14: 183-189
    CrossrefPubMedGoogle Scholar
  • 5 Rohde U, Hedback N, Gluud LL et al. Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2016; 18: 300-305
    CrossrefPubMedGoogle Scholar
  • 6 Koehestanie P, de Jonge C, Berends FJ et al. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Ann Surg 2014; 260: 984-992
    CrossrefPubMedGoogle Scholar
  • 7 Yu J, Marsh S, Hu J et al. The pathogenesis of nonalcoholic fatty liver disease: interplay between diet, gut microbiota, and genetic background. Gastroenterol Res Pract 2016; 2016: 2862173
    PubMedGoogle Scholar
  • 8 Hillenbrand A, Kiebler B, Schwab C et al. Prevalence of non-alcoholic fatty liver disease in four different weight related patient groups: association with small bowel length and risk factors. BMC Res Notes 2015; 8: 290
    CrossrefPubMedGoogle Scholar
  • 9 Lassailly G, Caiazzo R, Buob D et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology 2015; 149: 379-388 quiz e15-e16
    CrossrefPubMedGoogle Scholar
  • 10 Wong GL. Transient elastography: Kill two birds with one stone?. World J Hepatol 2013; 5: 264-274
    CrossrefPubMedGoogle Scholar
  • 11 Afdhal NH. Fibroscan (Transient Elastography) for the measurement of liver fibrosis. Gastroenterology & Hepatology 2012; 8: 605-607
    PubMedGoogle Scholar
  • 12 Kaswala DH, Lai M, Afdhal NH. Fibrosis assessment in nonalcoholic fatty liver disease (NAFLD) in 2016. Dig Dis Sci 2016 61: 1356-1364
    PubMedGoogle Scholar
  • 13 Kwok R, Choi KC, Wong GL et al. Screening diabetic patients for nonalcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut 2015
    PubMed
  • 14 Naveau S, Lamouri K, Pourcher G et al. The diagnostic accuracy of transient elastography for the diagnosis of liver fibrosis in bariatric surgery candidates with suspected NAFLD. Obes Surg 2014; 24: 1693-1701
    CrossrefPubMedGoogle Scholar
  • 15 Kumar M, Rastogi A, Singh T et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance?. J Gastroenterol Hepatol 2013; 28: 1194-1201
    CrossrefPubMedGoogle Scholar
  • 16 Chon YE, Jung KS, Kim SU et al. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver Int 2014; 34: 102-109
    CrossrefPubMedGoogle Scholar
  • 17 Wong VW, Vergniol J, Wong GL et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2012; 107: 1862-1871
    CrossrefPubMedGoogle Scholar
  • 18 Myers RP, Pomier-Layrargues G, Kirsch R et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012; 55: 199-208
    CrossrefPubMedGoogle Scholar
  • 19 de Ledinghen V, Wong VW, Vergniol J et al. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan(R). J Hepatol 2012; 56: 833-839
    CrossrefPubMedGoogle Scholar
  • 20 Boursier J, Zarski JP, de Ledinghen V et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology 2013; 57: 1182-1191
    CrossrefPubMedGoogle Scholar
  • 21 Wong VW-S, Vergniol J, Wong GL-H et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51: 454-462
    CrossrefPubMedGoogle Scholar
  • 22 de Ledinghen V, Vergniol J, Foucher J et al. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012; 32: 911-918
    CrossrefPubMedGoogle Scholar
  • 23 Calzadilla Bertot L, Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci. 2016; 17: 774
    CrossrefPubMedGoogle Scholar
  • 24 Wong VW, Wong GL, Yip GW et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 2011; 60: 1721-1727
    CrossrefPubMedGoogle Scholar
  • 25 Kim NH, Park J, Kim SH et al. Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population. Heart 2014; 100: 938-943
    CrossrefPubMedGoogle Scholar
  • 26 Kim D, Choi SY, Park EH et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology 2012; 56: 605-613
    CrossrefPubMedGoogle Scholar
  • 27 Arble DM, Sandoval DA, Seeley RJ. Mechanisms underlying weight loss and metabolic improvements in rodent models of bariatric surgery. Diabetologia 2015; 58: 211-220
    CrossrefPubMedGoogle Scholar
  • 28 Promrat K, Kleiner DE, Niemeier HM et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51: 121-129
    CrossrefPubMedGoogle Scholar
  • 29 Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol 2012; 56: 255-266
    CrossrefPubMedGoogle Scholar
  • 30 Haukeland JW, Konopski Z, Eggesbo HB et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 2009; 44: 853-860
    Google Scholar
  • 31 Armstrong MJ, Gaunt P, Aithal GP et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016; 387: 679-690
    CrossrefPubMedGoogle Scholar
  • 32 Barb D, Portillo-Sanchez P, Cusi K. Pharmacological management of nonalcoholic fatty liver disease. Metabolism 2016; 65: 1183-1195
    CrossrefPubMedGoogle Scholar
  • 33 Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology 2015; 149: 367-378 e5; quiz e14-e15
    CrossrefPubMedGoogle Scholar
  • 34 European Association for the Study of the Liver. Electronic address eee, European Association for the Study of D, European Association for the Study of O . EASL-EASD-EASO clinical practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388-1402
    CrossrefPubMedGoogle Scholar
  • 35 Caiazzo R, Lassailly G, Leteurtre E et al. Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study. Ann Surg 2014; 260: 893-898 discussion 8–9
    CrossrefPubMedGoogle Scholar
  • 36 de Jonge C, Rensen SS, Verdam FJ et al. Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes. Obes Surg. 2013; 23: 1354-1360
    CrossrefPubMedGoogle Scholar
  • 37 Gastaldelli A, Gaggini M, Daniele G et al. Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic PET study. Hepatology 2016
    PubMed
  • 38 Bonder A, Tapper EB, Afdhal NH. Contemporary assessment of hepatic fibrosis. Clin Liver Dis 2015; 19: 123-134
    CrossrefPubMedGoogle Scholar
  • 39 Tapper EB, Castera L, Afdhal NH. FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice. Clin Gastroenterol Hepatol 2015; 13: 27-36
    CrossrefPubMedGoogle Scholar
  • 40 Ciocan D, Lebrun A, Lamouri K et al. Adaptation of liver stiffness measurement depth in bariatric surgery candidates with suspected nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2016; 28: 1014-1020
    CrossrefPubMedGoogle Scholar
  • 41 Maggi U, Formiga A, Lauro R. Hepatic abscess as a complication of duodenal-jejunal bypass sleeve system and review of the literature. Surgery for obesity and related diseases: official journal of the American Society for Bariatric Surgery 2016
    PubMed
  • 42 Siegel E, Kahler G, Schepp W. Position paper of the professional societies to apply recommendation of endoscopic biliodigestive diversion in Germany – DDG/DGAV/DGVS -. Zeitschrift fur Gastroenterologie 2014; 52: 606-612
    Article in Thieme ConnectPubMedGoogle Scholar